Biophytis SA (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
BPTS Nasdaq 8731 http://www.biophytis.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biophytis SA (ADR)

Biophytis: The Combined General Meeting Will Be Held on Second Call on April 17, 2023 - Mar 30th, 2023 9:20 pm
Biophytis: Biophytis Presented Sarconeos (BIO101) As A Possible Treatment Candidate for Long COVID After Hospitalization During The 13th Annual International Conference on Frailty and Sarcopenia Resea - Mar 27th, 2023 6:20 am
Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program - Mar 17th, 2023 7:20 am
Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference - Mar 9th, 2023 7:20 am
Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19 - Mar 2nd, 2023 7:00 am
Biophytis Seeks Early Access Authorization For Its COVID-19 Treatment In France - Feb 27th, 2023 6:44 pm
Biophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19 - Feb 27th, 2023 7:20 am
Biophytis To Host a Combined General Shareholder’s Meeting on March 30, 2023 - Feb 23rd, 2023 7:20 am
Why Are Biophytis Shares Trading Higher In Premarket Today - Feb 2nd, 2023 1:31 pm
Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19 - Feb 2nd, 2023 7:20 am
Biophytis Publishes its Financial Results for the First Half of 2022 - Jan 31st, 2023 7:20 am
Biophytis: Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd - Jan 19th, 2023 7:00 am
Biophytis To Take Appropriate Measures After Receiving Nasdaq Deficiency Notice - Jan 12th, 2023 7:20 am
Biophytis Announces Its Participation in Two Major Investor Conferences in January, In the United States and In France: The JP Morgan Healthcare Conference and The Invest Securities Biomed - Jan 5th, 2023 7:20 am
Biophytis Organises a Webcast with Key Opinion Leaders (KOL) On the Phase 2-3 Cova Study Results of Sarconeos (Bio101) In the Treatment of Pneumonia in Covid-19 Patients at Risk of Respiratory Failure - Dec 1st, 2022 7:30 am
Biophytis Shares Gain After Detailed Data From Pivotal COVID-19 Treatment Study - Nov 3rd, 2022 1:13 pm
Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19 - Nov 3rd, 2022 7:20 am
Biophytis Publishes Its Key Financial Figures As at 30 June 2022, Announces a Restatement of the Financial Statements Published As of December 31st, 2021 and Provides an Update on the Operational Milestones - Oct 31st, 2022 11:10 pm
Biophytis Announces Receipt of Nasdaq Notice - Oct 26th, 2022 6:45 am
Biophytis Participates in H.C. Wainwright 24th Annual Global Investment Conference - Sep 15th, 2022 6:30 am